E3 ubiquitin ligases and human papillomavirus-induced carcinogenesis

Journal of International Medical Research

Volumn 42, Issue 2, 2014, Pages 247-260

  Lou, Zhifeng ^a   Wang, Sheng ^b  

^a ZHEJIANG UNIVERSITY   (China)

^b The 118th PLA Hospital   (China)

Author keywords

carcinogenesis; E3 ubiquitin ligase; Human papillomavirus; ubiquitin

Indexed keywords

CARCINOGENESIS; E3 UBIQUITIN LIGASE; HUMAN PAPILLOMAVIRUS; UBIQUITIN;

CELL TRANSFORMATION, NEOPLASTIC; FEMALE; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; SIGNAL TRANSDUCTION; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION; UTERINE CERVICAL NEOPLASMS; VIRAL PROTEINS;

EID: 84898685543     PISSN: 03000605     EISSN: 14732300     Source Type: Journal    
DOI: 10.1177/0300060513506655     Document Type: Review

References (98)

1. de Villiers EM,Fauquet C,Broker TR, et al.Classification of papillomaviruses.Virology. 2004;324:17-27.
2. Scheffner M,Whitaker NJ.Human papillomavirus-induced carcinogenesis and the ubiquitin-proteasome system.Semin Cancer Biol. 2003;13:59-67.
3. Einstein MH,Schiller JT,Viscidi RP, et al.Clinician's guide to human papillomavirus immunology: knowns and unknowns.Lancet Infect Dis. 2009;9:347-356.
4. Chaturvedi AK,Engels EA,Anderson WF, et al.Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States.J Clin Oncol. 2008;26:612-619.
5. Dayyani F,Etzel CJ,Liu M, et al.Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC).Head Neck Oncol. 2010;2:15-15.
6. Gillison ML,D'Souza G,Westra W, et al.Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers.J Natl Cancer Inst. 2008;100:407-420.
7. Syrjänen S.The role of human papillomavirus infection in head and neck cancers.Ann Oncol. 2010;21:vii243-vii245.
8. Zhou Q,Zhu K,Cheng H.Toll-like receptors in human papillomavirus infection.Arch Immunol Ther Exp (Warsz). 2013;61:203-215.
9. Mammas IN,Sourvinos G,Giannoudis A, et al.Human papilloma virus (HPV) and host cellular interactions.Pathol Oncol Res. 2008;14:345-354.
10. Glickman MH,Ciechanover A.The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction.Physiol Rev. 2002;82:373-428.
11. Ciechanover A.The ubiquitin-proteasome proteolytic pathway.Cell. 1994;79:13-21.
12. Ingham RJ,Gish G,Pawson T.The Nedd4 family of E3 ubiquitin ligases: functional diversity within a common modular architecture.Oncogene. 2004;23:1972-1984.
13. Scheffner M,Huibregtse JM,Vierstra RD, et al.The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53.Cell. 1993;75:495-505.
14. Fang S,Jensen JP,Ludwig RL, et al.Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53.J Biol Chem. 2000;275:8945-8951.
15. Joazeiro CA,Wing SS,Huang H, et al.The tyrosine kinase negative regulator c-Cbl as a RING-type, E2-dependent ubiquitin-protein ligase.Science. 1999;286:309-312.
16. Ang XL,Wade Harper J.SCF-mediated protein degradation and cell cycle control.Oncogene. 2005;24:2860-2870.
17. Chen ZJ.Ubiquitin signalling in the NF-kappaB pathway.Nat Cell Biol. 2005;7:758-765.
18. Johnson ES.Ubiquitin branches out.Nat Cell Biol. 2002;4:E295-E298.
19. Wing SS.Deubiquitinating enzymes-the importance of driving in reverse along the ubiquitin-proteasome pathway.Int J Biochem Cell Biol. 2003;35:590-605.
20. Schwarz SE,Rosa JL,Scheffner M.Characterization of human hect domain family members and their interaction with UbcH5 and UbcH7.J Biol Chem. 1998;273:12148-12154.
21. Huibregtse JM,Scheffner M,Howley PM.Cloning and expression of the cDNA for E6-AP, a protein that mediates the interaction of the human papillomavirus E6 oncoprotein with p53.Mol Cell Biol. 1993;13:775-784.
22. Thomas M,Banks L.Human papillomavirus (HPV) E6 interactions with Bak are conserved amongst E6 proteins from high and low risk HPV types.J Gen Virol. 1999;80:1513-1517.
23. Gross-Mesilaty S,Reinstein E,Bercovich B, et al.Basal and human papillomavirus E6 oncoprotein-induced degradation of Myc proteins by the ubiquitin pathway.Proc Natl Acad Sci U S A. 1998;95:8058-8063.
24. Gao Q,Kumar A,Singh L, et al.Human papillomavirus E6-induced degradation of E6TP1 is mediated by E6AP ubiquitin ligase.Cancer Res. 2002;62:3315-3321.
25. Kühne C,Banks L.E3-ubiquitin ligase/E6-AP links multicopy maintenance protein 7 to the ubiquitination pathway by a novel motif, the L2G box.J Biol Chem. 1998;273:34302-34309.
26. Srivenugopal KS,Ali-Osman F.The DNA repair protein, O(6)-methylguanine-DNA methyltransferase is a proteolytic target for the E6 human papillomavirus oncoprotein.Oncogene. 2002;21:5940-5945.
27. Xu M,Luo W,Elzi DJ, et al.NFX1 interacts with mSin3A/histone deacetylase to repress hTERT transcription in keratinocytes.Mol Cell Biol. 2008;28:4819-4828.
28. Kuballa P,Matentzoglu K,Scheffner M.The role of the ubiquitin ligase E6-AP in human papillomavirus E6-mediated degradation of PDZ domain-containing proteins.J Biol Chem. 2007;282:65-71.
29. Nakagawa S,Huibregtse JM.Human scribble (Vartul) is targeted for ubiquitin-mediated degradation by the high-risk papillomavirus E6 proteins and the E6AP ubiquitin-protein ligase.Mol Cell Biol. 2000;20:8244-8253.
30. Jing M,Bohl J,Brimer N, et al.Degradation of tyrosine phosphatase PTPN3 (PTPH1) by association with oncogenic human papillomavirus E6 proteins.J Virol. 2007;81:2231-2239.
31. Grm HS,Banks L.Degradation of hDlg and MAGIs by human papillomavirus E6 is E6-AP-independent.J Gen Virol. 2004;85:2815-2819.
32. Shimoji T,Murakami K,Sugiyama Y, et al.Identification of annexin A1 as a novel substrate for E6AP-mediated ubiquitylation.J Cell Biochem. 2009;106:1123-1135.
33. Wang LD,Yang YH,Liu Y, et al.Decreased expression of annexin A1 during the progression of cervical neoplasia.J Int Med Res. 2008;36:665-672.
34. Nag A,Germaniuk-Kurowska A,Dimri M, et al.An essential role of human Ada3 in p53 acetylation.J Biol Chem. 2007;282:8812-8820.
35. Hu Y,Ye F,Lu W, et al.HPV16 E6-induced and E6AP-dependent inhibition of the transcriptional coactivator hADA3 in human cervical carcinoma cells.Cancer Invest. 2009;27:298-306.
36. Dyson N,Guida P,Münger K, et al.Homologous sequences in adenovirus E1A and human papillomavirus E7 proteins mediate interaction with the same set of cellular proteins.J Virol. 1992;66:6893-6902.
37. Münger K,Werness BA,Dyson N, et al.Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product.EMBO J. 1989;8:4099-4105.
38. Boyer SN,Wazer DE,Band V.E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway.Cancer Res. 1996;56:4620-4624.
39. Jones DL,Thompson DA,Münger K.Destabilization of the RB tumor suppressor protein and stabilization of p53 contribute to HPV type 16 E7-induced apoptosis.Virology. 1997;239:97-107.
40. Huh K,Zhou X,Hayakawa H, et al.Human papillomavirus type 16 E7 oncoprotein associates with the cullin 2 ubiquitin ligase complex, which contributes to degradation of the retinoblastoma tumor suppressor.J Virol. 2007;81:9737-9747.
41. Zhang B,Chen W,Roman A.The E7 proteins of low- and high-risk human papillomaviruses share the ability to target the pRB family member p130 for degradation.Proc Natl Acad Sci U S A. 2006;103:437-442.
42. Tedesco D,Lukas J,Reed SI.The pRb-related protein p130 is regulated by phosphorylation-dependent proteolysis via the protein-ubiquitin ligase SCF (Skp2).Genes Dev. 2002;16:2946-2957.
43. Leechanachai P,Banks L,Moreau F, et al.The E5 gene from human papillomavirus type 16 is an oncogene which enhances growth factor-mediated signal transduction to the nucleus.Oncogene. 1992;7:19-25.
44. Bouvard V,Matlashewski G,Gu ZM, et al.The human papillomavirus type 16 E5 gene cooperates with the E7 gene to stimulate proliferation of primary cells and increases viral gene expression.Virology. 1994;203:73-80.
45. Stöppler MC,Straight SW,Tsao G, et al.The E5 gene of HPV-16 enhances keratinocyte immortalization by full-length DNA.Virology. 1996;223:251-254.
46. Zhang B,Srirangam A,Potter DA, et al.HPV16 E5 protein disrupts the c-Cbl-EGFR interaction and EGFR ubiquitination in human foreskin keratinocytes.Oncogene. 2005;24:2585-2588.
47. Fournier N,Raj K,Saudan P, et al.Expression of human papillomavirus 16 E2 protein in Schizosaccharomyces pombe delays the initiation of mitosis.Oncogene. 1999;18:4015-4021.
48. Bellanger S,Blachon S,Mechali F, et al.High-risk but not low-risk HPV E2 proteins bind to the APC activators Cdh1 and Cdc20 and cause genomic instability.Cell Cycle. 2005;4:1608-1615.
49. Reinstein E,Scheffner M,Oren M, et al.Degradation of the E7 human papillomavirus oncoprotein by the ubiquitin-proteasome system: targeting via ubiquitination of the N-terminal residue.Oncogene. 2000;19:5944-5950.
50. Oh KJ,Kalinina A,Wang J, et al.The papillomavirus E7 oncoprotein is ubiquitinated by UbcH7 and Cullin 1- and Skp2-containing E3 ligase.J Virol. 2004;78:5338-5346.
51. Kamio M,Yoshida T,Ogata H, et al.SOCS1 [corrected] inhibits HPV-E7-mediated transformation by inducing degradation of E7 protein.Oncogene. 2004;23:3107-3115.
52. Lin CH,Chang HS,Yu WC.USP11 stabilizes HPV-16E7 and further modulates the E7 biological activity.J Biol Chem. 2008;283:15681-15688.
53. Bellanger S,Demeret C,Goyat S, et al.Stability of the human papillomavirus type 18 E2 protein is regulated by a proteasome degradation pathway through its amino-terminal transactivation domain.J Virol. 2001;75:7244-7251.
54. Stewart D,Kazemi S,Li S, et al.Ubiquitination and proteasome degradation of the E6 proteins of human papillomavirus types 11 and 18.J Gen Virol. 2004;85:1419-1426.
55. Kehmeier E,Rühl H,Voland B, et al.Cellular steady-state levels of "high risk" but not "low risk" human papillomavirus (HPV) E6 proteins are increased by inhibition of proteasome-dependent degradation independent of their p53- and E6AP-binding capabilities.Virology. 2002;299:72-87.
56. Bellanger S,Tan CL,Nei W, et al.The human papillomavirus type 18 E2 protein is a cell cycle-dependent target of the SCFSkp2 ubiquitin ligase.J Virol. 2010;84:437-444.
57. Havard L,Delvenne P,Fraré P, et al.Differential production of cytokines and activation of NF-kappaB in HPV-transformed keratinocytes.Virology. 2002;298:271-285.
58. Nees M,Geoghegan JM,Hyman T, et al.Papillomavirus type 16 oncogenes downregulate expression of interferon-responsive genes and upregulate proliferation-associated and NF-kappaB-responsive genes in cervical keratinocytes.J Virol. 2001;75:4283-4296.
59. Mishra A,Bharti AC,Varghese P, et al.Differential expression and activation of NF-kappaB family proteins during oral carcinogenesis: role of high risk human papillomavirus infection.Int J Cancer. 2006;119:2840-2850.
60. Yuan H,Fu F,Zhuo J, et al.Human papillomavirus type 16 E6 and E7 oncoproteins upregulate c-IAP2 gene expression and confer resistance to apoptosis.Oncogene. 2005;24:5069-5078.
61. Zhou Q,Zhu K,Cheng H.Ubiquitination in host immune response to human papillomavirus infection.Arch Dermatol Res. 2011;303:217-230.
62. ten Dijke P,Hill CS.New insights into TGF-beta-Smad signalling.Trends Biochem Sci. 2004;29:265-273.
63. Inoue Y,Imamura T.Regulation of TGF-beta family signaling by E3 ubiquitin ligases.Cancer Sci. 2008;99:2107-2112.
64. Ki KD,Tong SY,Huh CY, et al.Expression and mutational analysis of TGF-beta/Smads signaling in human cervical cancers.J Gynecol Oncol. 2009;20:117-121.
65. Favre-Bonvin A,Reynaud C,Kretz-Remy C, et al.Human papillomavirus type 18 E6 protein binds the cellular PDZ protein TIP-2/GIPC, which is involved in transforming growth factor beta signaling and triggers its degradation by the proteasome.J Virol. 2005;79:4229-4237.
66. Lee DK,Kim BC,Kim IY, et al.The human papilloma virus E7 oncoprotein inhibits transforming growth factor-beta signaling by blocking binding of the Smad complex to its target sequence.J Biol Chem. 2002;277:38557-38564.
67. Renehan AG,Zwahlen M,Minder C, et al.Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis.Lancet. 2004;363:1346-1353.
68. Shen MR,Hsu YM,Hsu KF, et al.Insulin-like growth factor 1 is a potent stimulator of cervical cancer cell invasiveness and proliferation that is modulated by alphavbeta3 integrin signaling.Carcinogenesis. 2006;27:962-971.
69. Friedrich RE,Hagel C,Bartel-Friedrich S.Insulin-like growth factor-1 receptor (IGF-1R) in primary and metastatic undifferentiated carcinoma of the head and neck: a possible target of immunotherapy.Anticancer Res. 2010;30:1641-1643.
70. Rajah R,Valentinis B,Cohen P.Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta1 on programmed cell death through a p53- and IGF-independent mechanism.J Biol Chem. 1997;272:12181-12188.
71. Harris TG,Burk RD,Yu H, et al.Insulin-like growth factor axis and oncogenic human papillomavirus natural history.Cancer Epidemiol Biomarkers Prev. 2008;17:245-248.
72. Mannhardt B,Weinzimer SA,Wagner M, et al.Human papillomavirus type 16 E7 oncoprotein binds and inactivates growth-inhibitory insulin-like growth factor binding protein 3.Mol Cell Biol. 2000;20:6483-6495.
73. Santer FR,Moser B,Spoden GA, et al.Human papillomavirus type 16 E7 oncoprotein inhibits apoptosis mediated by nuclear insulin-like growth factor-binding protein-3 by enhancing its ubiquitin/proteasome-dependent degradation.Carcinogenesis. 2007;28:2511-2520.
74. Lin HP,Wang YP,Chiang CP.Expression of p53, MDM2, p21, heat shock protein 70, and HPV 16/18 E6 proteins in oral verrucous carcinoma and oral verrucous hyperplasia.Head Neck. 2011;33:334-340.
75. Chen X,Sturgis EM,Lei D, et al.Human papillomavirus seropositivity synergizes with MDM2 variants to increase the risk of oral squamous cell carcinoma.Cancer Res. 2010;70:7199-7208.
76. Matsumura T,Yoshihama Y,Kimura T, et al.p53 and MDM2 expression in oral squamous cell carcinoma.Oncology. 1996;53:308-312.
77. Wu X,Bayle JH,Olson D, et al.The p53-mdm-2 autoregulatory feedback loop.Genes Dev. 1993;7:1126-1132.
78. de Rozieres S,Maya R,Oren M, et al.The loss of mdm2 induces p53-mediated apoptosis.Oncogene. 2000;19:1691-1697.
79. Li M,Brooks CL,Wu-Baer F, et al.Mono- versus polyubiquitination: differential control of p53 fate by Mdm2.Science. 2003;302:1972-1975.
80. Gammoh N,Gardiol D,Massimi P, et al.The Mdm2 ubiquitin ligase enhances transcriptional activity of human papillomavirus E2.J Virol. 2009;83:1538-1543.
81. Bruzzone R,White TW,Paul DL.Connections with connexins: the molecular basis of direct intercellular signaling.Eur J Biochem. 1996;238:1-27.
82. Söhl G,Willecke K.Gap junctions and the connexin protein family.Cardiovasc Res. 2004;62:228-232.
83. King TJ,Fukushima LH,Hieber AD, et al.Reduced levels of connexin43 in cervical dysplasia: inducible expression in a cervical carcinoma cell line decreases neoplastic potential with implications for tumor progression.Carcinogenesis. 2000;21:1097-1109.
84. Tomakidi P,Cheng H,Kohl A, et al.Connexin 43 expression is downregulated in raft cultures of human keratinocytes expressing the human papillomavirus type 16 E5 protein.Cell Tissue Res. 2000;301:323-327.
85. Leykauf K,Salek M,Bomke J, et al.Ubiquitin protein ligase Nedd4 binds to connexin43 by a phosphorylation-modulated process.J Cell Sci. 2006;119:3634-3642.
86. Callaghan MJ,Russell AJ,Woollatt E, et al.Identification of a human HECT family protein with homology to the Drosophila tumor suppressor gene hyperplastic discs.Oncogene. 1998;17:3479-3491.
87. Clancy JL,Henderson MJ,Russell AJ, et al.EDD, the human orthologue of the hyperplastic discs tumour suppressor gene, is amplified and overexpressed in cancer.Oncogene. 2003;22:5070-5081.
88. Tomaic V,Pim D,Thomas M, et al.Regulation of the human papillomavirus type 18 E6/E6AP ubiquitin ligase complex by the HECT domain-containing protein EDD.J Virol. 2011;85:3120-3127.
89. Richardson PG,Barlogie B,Berenson J, et al.Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma: final time-to-event results from the SUMMIT trial.Cancer. 2006;106:1316-1319.
90. Nalepa G,Rolfe M,Harper JW.Drug discovery in the ubiquitin-proteasome system.Nat Rev Drug Discov. 2006;5:596-613.
91. Zhang Z,Wang H,Li M, et al.MDM2 is a negative regulator of p21WAF1/CIP1, independent of p53.J Biol Chem. 2004;279:16000-16006.
92. Vassilev LT,Vu BT,Graves B, et al.In vivo activation of the p53 pathway by small-molecule antagonists of MDM2.Science. 2004;303:844-848.
93. Roh JL,Kang SK,Minn I, et al.p53-Reactivating small molecules induce apoptosis and enhance chemotherapeutic cytotoxicity in head and neck squamous cell carcinoma.Oral Oncol. 2011;47:8-15.
94. Rubinstein LV,Shoemaker RH,Paull KD, et al.Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines.J Natl Cancer Inst. 1990;82:1113-1118.
95. Issaeva N,Bozko P,Enge M, et al.Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors.Nat Med. 2004;10:1321-1328.
96. Kim Y,Cairns MJ,Marouga R, et al.E6AP gene suppression and characterization with in vitro selected hammerhead ribozymes.Cancer Gene Ther. 2003;10:707-716.
97. Foster SA,Phelps WC.Zn(2+) fingers and cervical cancer.J Natl Cancer Inst. 1999;91:1180-1181.
98. Verdecia MA,Joazeiro CA,Wells NJ, et al.Conformational flexibility underlies ubiquitin ligation mediated by the WWP1 HECT domain E3 ligase.Mol Cell. 2003;11:249-259.